PMOS vs PCOS: what the new name means—and how PMOS is treated

If you have heard that PCOS is now called PMOS, you may be wondering whether your diagnosis has changed, whether you need new tests, and what the new name means for your treatment or fertility.

The short answer is that PMOS and PCOS describe the same condition. In May 2026, an international consensus renamed polycystic ovary syndrome (PCOS) polyendocrine metabolic ovarian syndrome (PMOS). The new name reflects the fact that this is not simply an ovarian condition and is not defined by having ovarian “cysts”. It can affect hormone signalling, ovulation, insulin sensitivity, metabolic health, skin, emotional wellbeing and fertility.

The change is being introduced gradually, with full implementation planned for the 2028 international guideline. During this transition, you will see both terms—PMOS (formerly PCOS)—used by healthcare professionals and online. Importantly, the name change does not invalidate an existing PCOS diagnosis or mean that everybody needs to be reassessed. Read the international announcement.

What does PMOS stand for?

PMOS stands for polyendocrine metabolic ovarian syndrome:

• Polyendocrine: several hormonal systems may be involved.

• Metabolic: insulin resistance and altered metabolic risk are important in many—but not all—people with the condition.

• Ovarian: ovarian function and ovulation can be affected.

• Syndrome: symptoms and their severity vary considerably between individuals.

The former name caused understandable confusion. The structures sometimes seen on ultrasound are usually numerous small ovarian follicles rather than pathological cysts. Some people with PMOS have polycystic ovarian morphology; others do not. Conversely, polycystic-looking ovaries on a scan do not, by themselves, establish the diagnosis.

What are the symptoms of PMOS?

PMOS can present differently at different life stages. Possible features include:

• irregular, infrequent or absent periods;

• irregular or absent ovulation;

• difficulty conceiving because of ovulatory dysfunction;

• acne or persistently oily skin;

• increased facial or body hair;

• scalp-hair thinning;

• insulin resistance, prediabetes or type 2 diabetes;

• weight gain or greater difficulty managing weight in some people;

• sleep apnoea;

• anxiety, depression, eating difficulties or reduced quality of life.

You do not need to have every symptom, and PMOS can occur at any body size. Symptoms also warrant proper assessment because thyroid disease, hyperprolactinaemia, non-classic congenital adrenal hyperplasia and several other endocrine conditions can produce a similar picture.

How is PMOS diagnosed?

In adults, diagnosis generally requires two of the following three features, after other causes have been excluded:

1. clinical or biochemical evidence of androgen excess;

2. irregular cycles or ovulatory dysfunction;

3. polycystic ovarian morphology on ultrasound—or, in appropriate adults, a raised anti-Müllerian hormone (AMH) result interpreted within a validated diagnostic pathway.

If irregular cycles and androgen excess are already present, an ultrasound or AMH test is not necessarily required to establish the diagnosis. AMH should not be used as a stand-alone test. Diagnosis during adolescence is more cautious because irregular cycles and acne can be part of normal puberty.

A complete assessment should extend beyond the ovaries. Depending on the individual, it can include blood pressure, glucose status, cholesterol, sleep symptoms, psychological wellbeing and endometrial protection. The international guideline recommends an oral glucose-tolerance test as the most accurate assessment of glycaemic status in PMOS, particularly when planning pregnancy or seeking fertility treatment. See the international evidence-based guideline.

How do you treat PMOS?

There is no single treatment that suits everyone and no supplement that “cures” PMOS. Treatment should be built around the person’s priorities: cycle control, androgen-related symptoms, metabolic health, fertility, emotional wellbeing—or a combination of these.

1. Lifestyle and metabolic health

Healthy eating, physical activity and behavioural support are recommended for everyone with PMOS, including people who are not trying to lose weight. Benefits can include improved cardiovascular fitness, metabolic health, quality of life and prevention of further weight gain.

There is no evidence that one named “PCOS diet” is universally superior. A sustainable pattern rich in vegetables, fruit, whole grains, pulses, high-quality protein, healthy fats and minimally processed foods is more useful than a highly restrictive plan. Exercise should ideally combine aerobic activity with resistance training, adapted to ability and preference.

Where a person has a higher weight, even modest weight reduction may improve metabolic health and ovulation—but care should remain respectful, individualised and free from weight stigma. Anti-obesity medication or bariatric/metabolic surgery may be considered for selected individuals under specialist guidance. Medicines used for weight management must be reviewed before conception because some should not be taken during pregnancy.

2. Irregular or absent periods

If pregnancy is not currently desired, the combined oral contraceptive pill is commonly used for irregular cycles and symptoms of androgen excess. A progestogen-only method, hormonal intrauterine system or intermittent prescribed progestogen may be used when oestrogen is unsuitable or contraception is not required.

This is not only about convenience. Very infrequent periods can allow the endometrium to remain exposed to oestrogen without regular progesterone opposition. Protecting the endometrium is therefore an important part of long-term care. Seek medical review for persistent abnormal bleeding rather than assuming it is caused by PMOS.

3. Insulin resistance and metabolic risk

Metformin may be considered—particularly where there is impaired glucose regulation, type 2 diabetes, higher metabolic risk or a BMI of 25 kg/m² or above. It can improve some metabolic measures and may help cycle regularity, but it is not a universal fertility treatment and is prescribed off-label for some PMOS indications in the UK.

Gastrointestinal side effects are common initially, so clinicians often increase the dose gradually. Long-term use can be associated with low vitamin B12, which may require monitoring. Treatment should be individualised by a GP or specialist rather than purchased or adjusted without clinical supervision. NICE PMOS management guidance.

4. Acne, excess hair and scalp-hair thinning

The combined pill can help acne and unwanted hair growth. Cosmetic and dermatological options—including topical acne therapy, eflornithine, laser or electrolysis—may also be useful.

Anti-androgen medicines such as spironolactone are sometimes considered when initial measures have not been sufficient. They require effective contraception because of potential fetal effects and should only be used under medical supervision.

5. Fertility and ovulation treatment

Many women with PMOS conceive naturally, but irregular ovulation can make conception slower or fertile days harder to predict. Fertility assessment should consider both partners and should not assume PMOS is the only possible factor.

For anovulatory infertility with no other infertility factor, the 2023 international guideline recommends letrozole as the first-line medication for ovulation induction. Clomifene, metformin or combinations may be considered in particular circumstances. Gonadotrophins, laparoscopic ovarian surgery or IVF may be offered when first-line treatment is unsuccessful or when other fertility factors are present.

Preconception care should also review blood pressure, glucose status, folate, vitamin D where indicated, medication safety, smoking, alcohol, sleep and mental health. PMOS is associated with increased pregnancy risks, including gestational diabetes and hypertensive disorders, so early, individualised antenatal care matters.

Can supplements help PMOS?

Supplements should be viewed as adjuncts to nutrition and clinical care, not treatments for PMOS or substitutes for ovulation-induction medication, endometrial protection or metabolic monitoring.

Myo-inositol

Myo-inositol has been studied for metabolic and reproductive outcomes in PMOS. Some trials report improvements in selected measures, but the evidence remains variable. The international guideline says inositol may be considered according to individual preference, while emphasising limited clinical benefits and insufficient evidence to recommend a specific type, combination or dose. A 2024 systematic review similarly concluded that the evidence is limited and inconclusive, although gastrointestinal adverse effects may be fewer than with metformin. Read the systematic review.

Coenzyme Q10

CoQ10 participates in mitochondrial energy production and antioxidant pathways. Research interest is strongest in preconception and assisted reproduction, including women with poor ovarian response; however, evidence of improved live-birth outcomes remains uncertain and the PMOS guideline does not position CoQ10 as a standard treatment.

PurerMama O Capsule provides 300 mg CoQ10 within a preconception formula alongside myo-inositol, glutathione, choline, methylfolate, zinc, selenium and vitamin D. This is best described as advanced preconception nutritional support, not as a product that treats PMOS, improves egg quality or guarantees pregnancy.

NAC and glutathione

N-acetyl cysteine (NAC) supplies cysteine used by the body to produce glutathione. Reviews have reported possible effects on selected hormonal, metabolic and reproductive markers in PMOS, but studies are heterogeneous and do not establish NAC as routine treatment. Read the 2025 systematic review.

NAC is therefore better considered as an optional, professionally reviewed preconception adjunct—not a universal essential. It should not be promoted as inducing ovulation, treating insulin resistance, improving implantation or preventing miscarriage. Routine use after a positive pregnancy test should be reviewed with the person’s doctor, fertility clinic or maternity team.

Folate, vitamin D and essential micronutrients

Anyone trying to conceive should follow UK preconception guidance, including 400 micrograms of folic acid daily before conception and through the first 12 weeks of pregnancy, unless a clinician prescribes the higher 5 mg dose for a recognised indication. Methylfolate in a food supplement should not be assumed to replace prescribed high-dose folic acid.

Vitamin D should be used in line with UK guidance and individual clinical need. Zinc contributes to normal fertility and reproduction when a product supplies the qualifying amount, while selenium contributes to protection of cells from oxidative stress. These authorised nutrient roles are different from claiming that a supplement treats PMOS or improves pregnancy rates.

A practical PMOS care pathway

1. Confirm the diagnosis. Exclude alternative endocrine causes and avoid relying on AMH or ultrasound alone.

2. Define your priorities. Periods, skin or hair symptoms, metabolic health and fertility may need different treatments.

3. Protect the endometrium. Discuss management if periods are very infrequent.

4. Assess long-term health. Review blood pressure, glucose, cholesterol, sleep and psychological wellbeing.

5. Build sustainable foundations. Choose eating and activity patterns that are realistic and culturally appropriate.

6. Use medication according to the treatment goal. The pill, progestogens, metformin, anti-androgens and fertility medicines are not interchangeable.

7. Use supplements as adjuncts. Check doses, duplication, medication interactions and plans for pregnancy.

8. Plan the transition into pregnancy. Review preconception supplements and medicines as soon as pregnancy is confirmed.

Frequently asked questions

Is PMOS the same as PCOS?

Yes. PMOS is the new name for the condition previously called PCOS. It is not a new disease, and the name change does not automatically alter an existing diagnosis or treatment plan.

Can PMOS be cured?

There is currently no cure, but symptoms, fertility and long-term metabolic risks can often be managed effectively with individualised lifestyle, medical, dermatological and fertility care.

What is the best treatment for PMOS?

The best treatment depends on the goal. Combined hormonal contraception is often used for irregular cycles and androgen symptoms; metformin may be appropriate for metabolic indications; and letrozole is the international guideline’s first-line medication for anovulatory infertility when no other infertility factor is present.

What supplements are best for PMOS fertility?

No supplement is established as a fertility treatment for PMOS. Myo-inositol, CoQ10 and NAC have emerging but incomplete evidence and should be considered adjuncts. Standard preconception folic-acid guidance remains essential.

Can I take CoQ10 or NAC once I am pregnant?

Do not assume that a preconception supplement should continue automatically in pregnancy. Review CoQ10, NAC and any complex fertility formula with your clinician or maternity team after a positive test.

Can I get pregnant naturally with PMOS?

Yes. Many women with PMOS conceive naturally. If cycles are very irregular, you are not ovulating, or conception is taking longer than expected, seek an assessment rather than relying on supplements alone.

The PurerMama approach: prepare the cell, nourish the journey

PMOS is a whole-body endocrine and metabolic condition, so good care must be broader than an ovarian scan or a collection of supplements. The strongest approach combines accurate diagnosis, sustainable metabolic support, protection of long-term health and timely fertility treatment where needed.

For women preparing for pregnancy, PurerMama’s Cellular Fertility Blueprint® places targeted nutrition in its proper context: supporting preconception nutritional status alongside—not instead of—clinical care. O Capsule brings together CoQ10, myo-inositol, glutathione, choline, methylfolate, zinc, selenium and vitamin D in one coherent preconception formula.

Suggested: Explore O Capsule and build your evidence-led preconception routine. If you have PMOS, take medication, are undergoing fertility treatment or receive a positive pregnancy test, review your full supplement plan with your healthcare professional.

Editorial and regulatory notes

• This article is educational and is not a substitute for diagnosis or personalised medical care.

Principal sources

1. Teede HJ et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet. 2026. PubMed record.

2. Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS. ASRM guideline.

3. NHS. Polyendocrine metabolic ovarian syndrome (PMOS). NHS overview.

4. NICE Clinical Knowledge Summaries. PMOS/PCOS management in adults. NICE CKS.

5. Fitz V et al. Inositol for PCOS: systematic review and meta-analysis informing the 2023 guideline. JCEM. 2024. PubMed.

6. Viña I et al. Efficacy of N-acetylcysteine in PCOS: systematic review and meta-analysis. 2025. PubMed.